Dupree Financial Group LLC Has $450,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Dupree Financial Group LLC lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 583 shares of the company’s stock after purchasing an additional 32 shares during the period. Dupree Financial Group LLC’s holdings in Eli Lilly and Company were worth $450,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. AMF Tjanstepension AB raised its stake in Eli Lilly and Company by 113.7% during the third quarter. AMF Tjanstepension AB now owns 331,786 shares of the company’s stock worth $293,964,000 after buying an additional 176,552 shares during the last quarter. Axiom Advisory LLC bought a new stake in shares of Eli Lilly and Company during the third quarter valued at approximately $345,000. Country Trust Bank increased its stake in Eli Lilly and Company by 1.6% during the 3rd quarter. Country Trust Bank now owns 95,627 shares of the company’s stock valued at $84,720,000 after purchasing an additional 1,500 shares in the last quarter. Artemis Investment Management LLP increased its position in shares of Eli Lilly and Company by 29.9% during the third quarter. Artemis Investment Management LLP now owns 55,474 shares of the company’s stock worth $49,147,000 after acquiring an additional 12,769 shares in the last quarter. Finally, Reliant Investment Management LLC increased its position in shares of Eli Lilly and Company by 4.4% during the third quarter. Reliant Investment Management LLC now owns 1,387 shares of the company’s stock worth $1,229,000 after acquiring an additional 59 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Price Performance

Shares of NYSE:LLY opened at $843.82 on Thursday. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The firm has a market capitalization of $801.05 billion, a PE ratio of 91.22, a P/E/G ratio of 1.72 and a beta of 0.42. Eli Lilly and Company has a twelve month low of $691.10 and a twelve month high of $972.53. The company has a 50-day moving average price of $785.46 and a two-hundred day moving average price of $843.28.

Eli Lilly and Company declared that its board has approved a share repurchase plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are typically a sign that the company’s management believes its shares are undervalued.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 10th. Investors of record on Friday, February 14th will be issued a $1.50 dividend. The ex-dividend date is Friday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. This represents a $6.00 annualized dividend and a yield of 0.71%. Eli Lilly and Company’s dividend payout ratio (DPR) is 64.86%.

Insider Buying and Selling

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of the firm’s stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have commented on LLY shares. Deutsche Bank Aktiengesellschaft decreased their price objective on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating for the company in a report on Monday, November 4th. Redburn Atlantic upgraded Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. StockNews.com downgraded shares of Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Wolfe Research started coverage on shares of Eli Lilly and Company in a report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Finally, Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a “buy” rating in a research note on Monday. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $997.50.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.